Micromet Inc. (MITI) Presents Positive Clinical Trial Results to Hematology Society
Biopharmaceutical company Micromet Inc. (Nasdaq: MITI) develops proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, and bases its discoveries on its proprietary antibody platform, BiTE. Yesterday the company released first interim data from a phase 2 clinical trial of BiTE antibody blinatumomab for patients with acute lymphoblastic leukemia (ALL). The company presented the clinical results at the 50th annual meeting of the American Society of Hematology December 6 to 9 in San Francisco. The results showed that ALL patients with minimal residual disease (MRD) after chemotherapy have a “significantly worse prognosis” than those without MRD. In Micromet’s…